Aurora Bio

Aurora Bio was a private clinical-stage biopharmaceutical company focused on systemic amyloid diseases. The company developed a platform combining amyloid-targeting immunotherapies with an imaging diagnostic intended to detect and monitor amyloid burden across multiple organs. Its disclosed lead program was AUR01, a PET radiotracer for systemic amyloidosis including AL, transthyretin, and leukocyte cell-derived chemotaxin-2 amyloidosis. Publicly available company-profile sources indicate the company was based in San Francisco, founded in 1996, led by Spencer Guthrie, and is now permanently closed. Available information on its broader pipeline and financing is limited.